Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Dog (Canine) Polyclonal KLB Primary Antibody for IHC, WB - ABIN2785343
Lu, Katsaros, Wiley, de la Longrais, Puopolo, Yu: Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression. in Cancer investigation 2008
obesity appears as the predominant determinant of the abnormalities in FGF21 (show FGF21 Antibodies) and FGF19 (show FGF19 Antibodies) levels. Opposite changes in beta-Klotho expression in fat and liver indicate potential tissue-specific alterations in the responsiveness to endocrine FGFs in obesity
ATF4 (show ATF4 Antibodies) signaling pathway is essential for mediating the effect of ER stress on beta-klotho expression.
Variants in genes involved in feedback regulation of bile acid synthesis (KLB, P=0.06 and FGFR4 (show FGFR4 Antibodies), P=0.09) were potentially associated with the irritable bowel syndrome-diarrhea subgroup with elevated serum C4.
In-depth DNA sequencing identified additional genetic coding and noncoding variants in KLB that are associated with fecal bile acids excretion or colonic transit in Irritable bowel syndrome-diarrhea.
betaKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt (show AKT1 Antibodies)/GSK-3beta (show GSK3b Antibodies)/cyclin D1 (show CCND1 Antibodies) signaling pathway.
KLB and FGFR1 (show FGFR1 Antibodies) form a 1:1 heterocomplex independent of the galectin lattice that transitions to a 1:2 complex upon the addition of FGF21 (show FGF21 Antibodies).
KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4 (show FGFR4 Antibodies) downstream signaling.
Differential specificity of endocrine FGF19 (show FGF19 Antibodies) and FGF21 (show FGF21 Antibodies) to FGFR1 (show FGFR1 Antibodies) and FGFR4 (show FGFR4 Antibodies) in complex with KLB.
Deletion of the D1 and the D1-D2 linker (the D1/linker region) from FGFR1c led to beta-Klotho-independent receptor activation by FGF21 (show FGF21 Antibodies), suggesting that there may be a direct interaction between FGF21 (show FGF21 Antibodies) and the D1/linker region-deficient FGFR1c.
Polymorphism KLB rs4975017 may influence the colonic transit response to colesevelam in female patients with irritable bowel syndrome with diarrhea.
Data show that enhancing beta-klotho (KLB) expression in adipose may sensitize to endogenous fibroblast growth factor 21 (FGF21 (show FGF21 Antibodies)), thus representing a novel strategy to combat metabolic disease.
Klotho (show KL Antibodies) is a novel player in the retina, with a clear connection to photoreceptor cell death as well as with an influence on retinal organization.
Mice lacking the FGF21 (show FGF21 Antibodies) co-receptor, beta-Klotho, in the suprachiasmatic nucleus are refractory to the inhibitory effect of FGF21 (show FGF21 Antibodies) on female fertility.
The effects of FGF21 (show FGF21 Antibodies) are mediated through beta-Klotho expression in the suprachiasmatic nucleus of the hypothalamus and the dorsal vagal complex of the hindbrain.
betaKlotho is required for fibroblast growth factor 21 (show FGF21 Antibodies) effects on growth and metabolism.
demonstrate the first manifest evidence revealing that whereas alpha-Kl (show KL Antibodies) and beta-Kl are required for FGF23 (show FGF23 Antibodies) and FGF15/hFGF19-mediated signaling pathways in vivo, respectively, beta-Kl appears not to be essential for FGF21 (show FGF21 Antibodies)-mediated signal transduction in vivo.
In contrast to wild-type FGF23 (show FGF23 Antibodies), FGF23 (show FGF23 Antibodies)-21c (a variant of FGF23 (show FGF23 Antibodies) where the C-terminal domain of FGF23 (show FGF23 Antibodies) was replaced with the corresponding regions from FGF21 (show FGF21 Antibodies)), FGF23 (show FGF23 Antibodies)-21c gained the ability to activate FGFR1c and FGFR2c in the presence of betaKlotho.
Contributes to the transcriptional repression of cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis. Probably inactive as a glycosidase. Increases the ability of FGFR1 and FGFR4 to bind FGF21 (By similarity).
, klotho beta like
, klotho beta-like protein
, klotho beta, pseudogene 1